Hudes G - Search Results

1

Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug.

Tew KD, Glusker JP, Hartley-Asp B, Hudes G, Speicher LA. Tew KD, et al. Among authors: hudes g. Pharmacol Ther. 1992 Dec;56(3):323-39. doi: 10.1016/0163-7258(92)90023-s. Pharmacol Ther. 1992. PMID: 1301594 Review.

2

Phase I clinical and pharmacologic trial of intravenous estramustine phosphate.

Hudes G, Haas N, Yeslow G, Gillon T, Gunnarsson PO, Ellman M, Nordle O, Eriksson B, Miller L, Cisar L, Kopreski M, Viaro D, Hartley-Asp B. Hudes G, et al. J Clin Oncol. 2002 Feb 15;20(4):1115-27. doi: 10.1200/JCO.2002.20.4.1115. J Clin Oncol. 2002. PMID: 11844837 Clinical Trial.

3

Estramustine-based chemotherapy.

Hudes G. Hudes G. Semin Urol Oncol. 1997 Feb;15(1):13-9. Semin Urol Oncol. 1997. PMID: 9050135 Review.

4

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.

Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B. Hudes G, et al. J Clin Oncol. 1999 Oct;17(10):3160-6. doi: 10.1200/JCO.1999.17.10.3160. J Clin Oncol. 1999. PMID: 10506613 Clinical Trial.

5

Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.

Haas N, Roth B, Garay C, Yeslow G, Entmacher M, Weinstein A, Rogatko A, Babb J, Minnitti C, Flinker D, Gillon T, Hudes G. Haas N, et al. Among authors: hudes g. Urology. 2001 Jul;58(1):59-64. doi: 10.1016/s0090-4295(01)01011-1. Urology. 2001. PMID: 11445480 Clinical Trial.

6

Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer.

Haas NB, Manola J, Hudes G, Citrin DL, Kies MS, Davis TE; Eastern Cooperative Oncology Group Study PH882. Haas NB, et al. Among authors: hudes g. Am J Clin Oncol. 2000 Dec;23(6):589-92. doi: 10.1097/00000421-200012000-00012. Am J Clin Oncol. 2000. PMID: 11202803 Clinical Trial.

7

Early stopping designs based on progression-free survival at an early time point in the initial cohort.

Litwin S, Wong YN, Hudes G. Litwin S, et al. Among authors: hudes g. Stat Med. 2007 Oct 30;26(24):4400-15. doi: 10.1002/sim.2866. Stat Med. 2007. PMID: 17345568

8

Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.

Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S; Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group. Fizazi K, et al. Among authors: hudes g. Lancet Oncol. 2007 Nov;8(11):994-1000. doi: 10.1016/S1470-2045(07)70284-X. Epub 2007 Oct 17. Lancet Oncol. 2007. PMID: 17942366

9

Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.

Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, Hussain M. Vaishampayan U, et al. Among authors: hudes g. Clin Cancer Res. 2000 Nov;6(11):4205-8. Clin Cancer Res. 2000. PMID: 11106233 Clinical Trial.

10

Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.

Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G. Wong YN, et al. Among authors: hudes g. J Clin Oncol. 2012 Oct 1;30(28):3545-51. doi: 10.1200/JCO.2012.41.9572. Epub 2012 Aug 27. J Clin Oncol. 2012. PMID: 22927525 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

176 results

Search Page

Filters